

1 **TITLE:** ONE ASSAY TO TEST THEM ALL: COMPARING MULTIPLEX ASSAYS FOR
2 EXPANSION OF RESPIRATORY VIRUS SURVEILLANCE

3
4 **AUTHORS**

5 Narjis BOUKLI¹; Claude FLAMAND²; Kim Lay CHEA¹; Leangyi HENG¹; Seangmai KEO¹;
6 Kimhoung SOUR¹; Sophea IN¹; Panha CHHIM¹; Bunthea CHHOR¹; Lomor KRUY¹; Jelena D
7 M FEENSTRA³; Manoj GANDHI³; Obiageli OKAFOR³; Camilla ULEKLIEV³; Heidi
8 AUERSWALD¹; Viseth Srey HORM¹; Erik A KARLSSON^{1*}

9
10 ¹Virology Unit, National Influenza Center, WHO H5 Regional reference Laboratory, World
11 Health Organization COVID-19 Global Referral Laboratory, Institute Pasteur du Cambodge,
12 Phnom Penh, Cambodia.

13 ²Epidemiology Unit, Institute Pasteur du Cambodge, Phnom Penh, Cambodia.

14 ³Thermo Fisher Scientific, South San Francisco CA, United States

15
16 ***Corresponding author:**

17 Erik A. Karlsson, Ph.D.

18 Virology Unit, Institut Pasteur du Cambodge

19 5 Monivong Blvd. PO Box #983, Phnom Penh, Cambodia

20 Phone: +855 70 297 804

21 Email: ekarlsson@pasteur-kh.org

22
23 **WORD COUNT:** Abstract 225, Manuscript 2499

24 **KEYWORDS:**

25 SARS-CoV-2; Influenza virus; Respiratory syncytial virus; COVID-19; multiplex assay; real-
26 time PCR.

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48 **ABSTRACT**

49 **Background:** Molecular multiplex assays (MPAs) for simultaneous detection of severe acute
50 respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza and respiratory syncytial virus
51 (RSV) in a single RT-PCR reaction reduce time and increase efficiency to identify multiple
52 pathogens with overlapping clinical presentation but different treatments or public health
53 implications.

54 **Methods:** Clinical performance of XpertXpress[®] SARS-CoV-2/Flu/RSV (Cepheid, GX),
55 TaqPath[™] COVID-19, FluA/B, RSV Combo kit (Thermo Fisher Scientific, TP), and
56 PowerChek[™] SARS-CoV-2/Influenza A&B/RSV Multiplex RT-PCR kit II (KogeneBiotech,
57 PC) was compared to individual Standards of Care (SoC). Thirteen isolates of SARS-CoV-2,
58 human seasonal influenza, and avian influenza served to assess limit of detection (LoD). Then,
59 positive and negative residual nasopharyngeal specimens, collected under public health
60 surveillance and pandemic response served for evaluation. Subsequently, comparison of
61 effectiveness was assessed.

62 **Results:** The three MPAs confidently detect all lineages of SARS-CoV-2 and influenza viruses.
63 MPA-LoDs vary from 1-2 Log₁₀ differences from SoC depending on assay and strain. Clinical
64 evaluation resulted in overall agreement between 97% and 100%, demonstrating a high accuracy
65 to detect all targets. Existing differences in costs, testing burden and implementation constraints
66 influence the choice in primary or community settings.

67 **Conclusion:** TP, PC and GX, reliably detect SARS-CoV-2, influenza and RSV simultaneously,
68 with reduced time-to-results and simplified workflows. MPAs have the potential to
69 enhance diagnostics, surveillance system, and epidemic response to drive policy on prevention
70 and control of viral respiratory infections.

71 **IMPORTANCE:**

72 Viral respiratory infections represent a major burden globally, weighed down by the COVID-19
73 pandemic, and threatened by spillover of novel zoonotic influenza viruses. Since respiratory
74 infections share clinical presentations, identification of the causing agent for patient care and
75 public health measures requires laboratory testing for several pathogens, including potential
76 zoonotic spillovers. Simultaneous detection of SARS-CoV-2, influenza, and RSV in a single RT-
77 PCR accelerates time from sampling to diagnosis, preserve consumables, and streamline human
78 resources to respond to other endemic or emerging pathogens. Multiplex assays have the
79 potential to sustain and even expand surveillance systems, can utilize capacity/capability
80 developed during the COVID-19 pandemic worldwide, thereby strengthening
81 epidemic/pandemic preparedness, prevention, and response.

82

83 **BACKGROUND**

84 Aside from novel coronavirus disease 2019 (COVID-19), respiratory infections with viral
85 pathogens remain a major global burden [1–3]. Since numerous respiratory viruses circulate
86 concurrently with similar clinical presentations, diagnosis requires laboratory testing for several
87 pathogens. Any delays in accurate and timely identification can compromise patient care [4].

88 Real-time polymerase chain reaction (RT-PCR) on upper respiratory tract (URT) swabs
89 is the gold standard for diagnosis of viral respiratory infections (VRIs) [5]. Between 2020 and
90 2022, public health measures to constrain COVID-19 significantly altered incidence of VRIs [6].
91 However, with reduction of restrictions and fatigue over prevention behaviors, both influenza
92 and respiratory syncytial virus (RSV) are resurging [7,8]. Co-infections can increase severity and
93 mortality [9,10]. In addition, spillovers of novel zoonotic influenza viruses continually represent
94 a human threat [11,12]. Funding issues, disruptions in reagent procurement and supply chains,
95 and inadequate human resources reduce diagnostic testing capacity, especially under pandemic
96 conditions. Therefore, improvement of VRI surveillance needs to account not only for multiple
97 pathogens and their potential genetic and seasonal changes, but also for human resources,
98 capacity, and cost.

99 Molecular multiplex assays (MPAs) allowing detection of several pathogens in a single
100 RT-PCR have demonstrated utility for diagnostics of influenza and RSV [13]. Early in the
101 COVID-19 pandemic, manufacturers modified existing MPAs to simultaneously detect severe
102 acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [5,14]. Both the United States and
103 Wales recommend MPA integration to detect SARS-CoV-2 and influenza in their public health
104 strategies [15,16]. Considering the co-circulation of respiratory viruses and suggested expansion
105 of testing in global surveillance, MPAs may be an attractive option [17,18]. However, viral

106 evolution, genetic bottlenecks , and emergence of novel avian influenza (AIV) strains could
107 impair viral detection [19,20].

108 Comparison between MPAs and standard protocols allows evaluation of the clinical
109 performance, as well as cost and testing burden for three commercial multiplex RT-PCR assays
110 intended to simultaneously detect SARS-CoV-2, influenza, and RSV.

111

112 **METHODS**

113 *Assays*

114 Three MPAs available and easily implemented in Cambodia were performed according to
115 manufacturers' protocols (Table 1).

116 1. **XpertXpress™ SARS-CoV-2/Flu/RSV test (GX)** (Cepheid, CA, USA), a closed
117 unitary MPA, integrates specimen extraction, RT-PCR, and target detection [21]. A
118 GeneXpert Xpress XVI-16 instrument (Cepheid) served to run cartridges, and instrument
119 software generated result interpretation.

120 2. **TaqPath™ COVID-19, FluA/B, RSV Combo Kit (TP)** (Thermo Fisher Scientific, MA,
121 United States) is a MPA with two targets for each virus [22]. RT-PCR was performed on
122 the QuantStudio™ 5 RT-PCR Instrument, 0.2 mL block (Applied Biosystems, MA,
123 USA) and results were analyzed using the Pathogen Interpretive Software CE-IVD
124 Edition v1.1.0 (Applied Biosystems).

125 3. **PowerChek™ SARS-CoV-2, Influenza A&B, RSV Multiplex Real-time PCR Kit II**
126 (PC) (KogeneBiotech, Inchon, Korea), a MPA with one targeted gene for each virus [23],
127 was performed on the CFX96™ RT-PCR Detection System (Bio-Rad Laboratories, CA,
128 USA) and results analyzed with CFX96™ software.

129 Standard of care assays (SoC) utilized at IPC for the detection of SARS-CoV-2 (CoV-SoC),
130 influenza A virus (IAV-SoC), influenza B virus (IBV-SoC) and RSV (RSV-SoC), consisting of
131 single RT-PCR tests (Table 1), served as reference [24–27]. In addition, IAV samples were
132 tested using Food and Agriculture Organization of United Nations (FAO) recommended primers
133 and probes developed by the Australian Center for Disease Prevention for the detection of M
134 gene from avian influenza viruses (AIV) in Asia [28]. All SoC and FAO were performed on a
135 CFX96™ instrument and results analyzed with the corresponding software.

136

137 *Study specimens*

138 In-house Cambodian viral isolates, including several variants of SARS-CoV-2 and
139 subtypes of human seasonal influenza, and AIV (Table 2) were heat-inactivated and used to
140 assess the limit of detection (LoD) of each assay. For each isolate, a serial-dilution was prepared
141 in standard Viral Transport Media (VTM) and stored at -70°C. Immediately after thawing, 300µl
142 of sample was tested with GX and 400µl was extracted with the MagMAX™ Viral/Pathogen II
143 Nucleic Acid Isolation Kit on a KingFisher Flex system (Thermo Fisher Scientific), using the
144 volume recommended by TP instructions for use, and RNA eluted with 50µl nuclease-free water.
145 Each 10-fold dilution was tested in triplicate with SoC. End-point dilution was defined as lowest
146 dilution at which all replicates were positive. Subsequently, each viral isolate was tested with
147 GX, TP, PC and SoC in parallel on the same day, at the previously determined end-point dilution
148 and a minimum of two half-log₁₀ dilutions on either side of the LoD.

149 To assess clinical accuracy, residual URT specimens collected in VTM were selected
150 based on routine results obtained under public health surveillance for influenza (IAV n= 84, IBV
151 n= 5) and RSV (n=32), and pandemic response for SARS-CoV-2 (n= 58), upon availability and

152 volume of stored samples (supplementary table 1). Different lineages were selected based on
153 molecular and sequencing results. Samples previously tested negative for all targets were also
154 included (n=126). Similar to viral isolates, 300µl of sample were used for GX testing and 400µl
155 for extraction. Extracted RNA served for side-by-side testing with TP, PC, and SoC, performed
156 on the same day. As amount of RNA for each sample was limited to re-test with SoC, routine
157 negative results were utilized for comparison in the following cases: for IAV, IBV, and RSV
158 among the SARS-CoV-2 samples; for IBV and RSV for IAV samples; for IAV and RSV for IBV
159 samples; for SARS-CoV-2 and IAV/IBV among negative samples. Influenza and RSV samples
160 collected during influenza/RSV seasons in 2016-2019 were negative for SARS-CoV-2.
161 However, if one targeted virus was detected with any MPA, the related SoC was performed
162 using the same RNA. For 31/84 IAV specimens, remaining volume was not sufficient to perform
163 GX testing in addition to extraction.

164

165 *Statistical analysis*

166 For each assay, individual cycle threshold (Ct) values (Ct-values) and interpretation as
167 positive or negative according to test cut-off were recorded for each viral isolate and clinical
168 sample. Three (SARS-CoV-2; influenza; RSV) results for TP or 4 (SARS-CoV-2; IAV; IBV;
169 RSV) for GX, PC and SoC were provided for each sample. Comparison was performed for each
170 virus individually. Difference between LoD with SoC and each MPA (D-LoD) was calculated
171 for each viral isolate. D-LoD resulted in 0 when MPA and SoC had the same LoD, ≥ 1 if MPA
172 LoD was higher than SoC and < 0 if MPA LoD was lower than SoC. Sensitivity, specificity,
173 positive and negative predictive values (PPA/NPA) were calculated using STATA statistical
174 software (v12.1, College Station, TX, USA). Overall accuracy to detect viruses in clinical

175 samples for GX, TP and PC was assessed by percent agreement, corresponding to the proportion
176 of identical results between each MPA evaluated and SoC for each virus, and 95% confidence
177 intervals (95% CI).

178

179 *Assessment of utility*

180 Total turnaround time per specimen, including extraction, RT-PCR, and interpretation of results
181 were compared. Cost comparison accounted for reagents and shipments to Cambodia at current
182 pricing structures. Other criteria to help drive choice for suitability included the volume of
183 sample for extraction/assay, amount of RNA for RT-PCR, equipment requirements,
184 practicability of interpretation software, result type obtained for each targeted virus.

185

186 **RESULTS**

187 *Limit of Detection*

188 The three MPAs consistently detected all selected viral strains with D-LoDs ranging from -2 to
189 +2 Log₁₀ dilutions according to strains and assays (Table 2). A higher D-LoD occurred on GX
190 for 5/13 isolates: SARS-CoV-2 Alpha and Omicron variants and recent A(H1N1), A(H3N2-
191 2022) IAV and A(H9N2) AIV from human sample, but LoD was equivalent or lower for other
192 isolates. TP had equivalent (6/13 isolates) or slightly better LoD (5/13 isolates) compared to SoC
193 except for A(H7N4). For PC, all LoDs were equivalent or slightly better than SoC.

194

195 *Performance on clinical samples*

196 Median and range of Ct-values on GX were equivalent to SoC, but lower using TP and PC
197 (Figure 1). TP and PC adequately detected all selected positive samples from all lineages and all

198 negative samples with sensitivity and specificity over 95% (Supplemental Table 2). GX
199 identified all but four samples, for which the test failed to detect RSV. Discordant results
200 occurred in 14 samples on the remaining targets (Supplemental Table 3). Among two samples
201 with RSV/SARS-CoV-2 co-infection, none of the MPAs detected SARS-CoV-2 in the first, and
202 PC failed to detect SARS-CoV-2 in the second sample. Among the 4/32 RSV samples (12.5%)
203 not detected with GX, three were mono-infections. The last one had an IAV/RSV co-infection.
204 TP also failed to detect RSV in this sample. Eight additional samples had a positive result for one
205 target but were not detected by SoC or other MPA: two had positive result only with TP (1
206 influenza; 1 RSV) and six only with PC (1 SARS-CoV-2; 1 IAV; 3 IBV; 1 RSV).
207 Overall, positive and negative predictive values (PPV, NPV) ranged between 97% and 100%,
208 except for detection of IBV using PC which dropped to 62.5%. However, overall accuracy
209 between SoC and MPA ranged between 97% and 100% of agreement (Table 3).

210

211 *Assessment of utility*

212 MPAs provide results for detection of SARS-CoV-2, influenza, and RSV in a single RT-PCR
213 assay compared to five SoC RT-PCR reactions to get the same information, with variable costs,
214 testing burden, and implementation parameters (Table 4). Manufacturer instructions for GX and
215 TP have strictly defined volume of sample/elution and RNA . PC, similar to SoC, allows the use
216 of different sample volumes according to extraction kit. GX and TP are designed for
217 manufacturer-specific instruments. SoC and PC can be utilized on any instrument providing
218 more than two and four optical channels respectively. Run time of 90min per run for 94 samples
219 with TP and PC is similar to SoC but simultaneously provide results for all targets. GX integrates
220 the process from extraction to result, but only for one sample per run. TP required specific

221 training to use the QuantStudio 5 and CE-IVD software for interpretation, while SoC and PC
222 were interpreted on current laboratory software.

223

224 **DISCUSSION**

225 Incorporation of MPAs into routine surveillance of SARS-CoV-2, influenza and RSV is critical
226 to expand pathogen detection while minimizing costs and constrain on human resources within
227 existing capacities/capabilities. A side-by-side comparison of GX, TP and PC using the same
228 large set of viral isolates, including avian influenza, and clinical samples was critical for
229 evaluation, especially for limited resource settings with high probability of AIV spillover.

230 GX, TP and PC consistently detected all viral lineages of SARS-CoV-2 and influenza;
231 however, GX had slightly higher LoD compared to SoC. Decreased GX testing volume
232 compared to extraction possibly contributed to this discrepancy. Each MPA demonstrated high
233 accuracy to detect all viruses in clinical samples. Overall, median and range of Ct-values
234 obtained with TP and PC were lower than with SoC and GX. Differences in sample volume and
235 lower number of samples tested with GX could affect these values. Discrepancies between
236 assays did occur. One SARS-CoV-2 infection was not detected by PC, and one and four RSV
237 were not detected by TP and GX, respectively. Low viral load (Ct=38-39) by SoC close to LoD
238 and storage issues could impair detectability. Difference in sample testing volume could impact
239 detection with GX. Unfortunately, remaining sample volume did not allow repeated GX testing.
240 Eight samples had a positive result for one target, but were negative with SoC and other MPAs
241 and were considered as false positive results.

242 Most commercial tests are not specifically designed to identify/distinguish AIV or novel
243 IAV. However, detection of zoonotic AIV infection is paramount, especially in endemic

244 countries such as Cambodia [29], and for pandemic prevention and preparedness globally. GX
245 package insert does assert the test adequately detects AIV [21]; however, PC and TP have no
246 previous data available. This study indicates MPAs can likely identify AIV cases with high
247 accuracy to detect all targets in clinical samples. All variants of SARS-CoV-2 circulating in
248 Cambodia during the collection period were detected.

249 Previous evaluations of GX reported a high concordance using retrospective clinical
250 samples compared to other Cepheid assays and several MPAs. In the UK [14], Netherlands [30],
251 and Hong Kong [31], GX had 95-99.64% PPA and 100% NPA for targets compared to SoC. No
252 false positive results were observed with GX in this study, but some were previously reported for
253 SARS-CoV-2/RSV co-infections [30,31]. A previous version of PC was evaluated in South
254 Korea with 100% PPA/NPA for SARS-CoV-2, IAV, and IBV and 93.1%/100% for RSV versus
255 comparator [32]. TP has been evaluated using nasopharyngeal specimens with PPA/NPA at
256 98.2%/100%, 100%/96.5%, and 98.2%/92.8% for SARS-CoV-2, influenza, and RSV,
257 respectively, compared to reference assays [22]. Detection accuracy in the present study of 97%-
258 100% PPA for all targets is similar to these previous findings.

259 In addition to detection efficiency, MPAs' utility is critical for routine use in laboratories.
260 Each GX cartridge only tests one sample at-a-time and is more expensive than other MPAs.
261 However, GX provides fastest results with minimal sample handling, an advantage for
262 emergency cases, reduced sample loads, and/or restricted human resources. Moreover, GX does
263 not require extensive expertise in techniques or interpretation. TP and PC minimize volume of
264 RNA required, and significantly reduce instrument occupation time, potentially critical during
265 periods with high testing demand. Result interpretation is provided automatically using specific
266 software for TP and GX, with TP requiring review of amplification curves [22]. PC and SoCs

267 require user interpretation, allowing flexibility but also need expertise to avoid misinterpretation
268 and introduction of potential technical error.

269 A prospective design was not possible in this study and retrospective investigation was
270 conducted on stored samples, potentially resulting in selection bias and reduced sample quality.
271 This impact was probably limited by selection based on available volume versus specific viral
272 characteristics. Sample volume and/or extracted RNA was too limited to repeat all SoC for all
273 samples, thus some routine results were included from time of reception. However, if any
274 targeted virus was detected with MPA, the same extracted RNA was retested with corresponding
275 SoC. A few samples with low viral loads and limited IBV sample number restricted some further
276 investigations. Finally, determination of LoD by viral copy number requires extensive *in vitro*
277 assessment and electron microscopy, which is not readily available in Cambodia. Future
278 experiments with tittered viral isolates will add to the assessment of LoD.

279 The reality of overlapping clinical presentations of concurrently circulating viruses,
280 funding and reagent constraints, and limited human resources require integration of MPAs into
281 routine VRI surveillance. Timely diagnosis decreases unnecessary laboratory testing, minimizes
282 use of antibiotics, and maximizes effectiveness of measures to control infection. Appropriate and
283 early antiviral treatment reduces complications, hospitalizations, and mortality [33].
284 Simultaneous detection of SARS-CoV-2, influenza, and RSV in a single test accelerates time
285 from sampling to diagnosis, and can utilize capacity/capability developed during the COVID-19
286 pandemic. MPAs also preserve consumables, and streamline human resources to respond to other
287 endemic or emerging pathogens. As result, MPAs have the potential to sustain and even expand
288 surveillance systems, thereby strengthening understanding of seasonal pathogens, availability for
289 vaccine development, and epidemic/pandemic preparedness, prevention, and response.

290 **ACKNOWLEDGMENTS**

291 The authors would like to acknowledge the Cambodian Ministry of Health and Cambodian
292 Communicable Disease Control Department, Rapid Response Team members, all of the
293 Provincial Health Departments, and the doctors, nurses, and staff involved in the COVID-19
294 response in Cambodia. We thank all of patients who supplied samples for this evaluation. We
295 also thank the technicians and staff at Institut Pasteur du Cambodge in the Virology and
296 Epidemiology/Public Health Units involved in this work, especially all of the tirelessly dedicated
297 COVID and Influenza teams.

298

299 **CONFLICT OF INTEREST**

300 This work was supported by Thermo Fisher Scientific, who loaned the QuantStudio 5TM RT-
301 PCR, 96 well, 0.2 mL instrument (Applied Biosystems) and laptop to IPC for the purpose of the
302 study, provided TaqPathTM COVID-19, FluA/B, RSV Combo Kits, and co-authors included were
303 involved in the study design, analysis and interpretation of TaqPath results and reviewed the
304 report.

305

306 **FUNDING SOURCE**

307 This work was supported by Thermo Fisher Scientific, who loaned the QuantStudio 5TM RT-
308 PCR, 96 well, 0.2 mL instrument (Applied Biosystems) and laptop to IPC for the purpose of the
309 study, provided TaqPathTM COVID-19, FluA/B, RSV Combo Kits, and co-authors included were
310 involved in the study design, analysis and interpretation of TaqPath results and reviewed the
311 report. French Agency for Development funded the ECOMORE II project and a COVID-19 top-
312 up (project No. CZZ 2146 01A), providing payed salary to NB for a senior medical virologist

313 position under a temporary contract with the Institut Pasteur du Cambodge. H. A. is supported by
314 the German Centre for International Migration and Development (CIM). Influenza, COVID-19,
315 and RSV work at IPC and E.A.K are supported, in part, by the World Health Organization and
316 the Food and Agriculture Association of the United Nations. COVID-19 work is supported, in
317 part, E.A.K is funded, in part, by the Pasteur International Center for Research on Emerging
318 Infectious Diseases (PICREID) National Institutes of Health, Department of Health and Human
319 Services -funded project (*IU01AII51758-01*).

320

321 **ETHICAL APPROVAL STATEMENT**

322 This study was approved by the Cambodian National Ethics Committee for Health Research
323 (N°050 NECHR, 2022). Since samples were obtained as part of the national influenza
324 surveillance system and as part of outbreak response for SARS-CoV-2, requirement for informed
325 consent was waived for their use in the study. All samples were de-identified and the database
326 contained no patient information.

327

328

329

330

331

332

333 **REFERENCES**

- 334 [1] World Health Organization, WHO The top 10 causes of death, (2020).
335 <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>.
- 336 [2] J. Perin, A. Mulick, D. Yeung, F. Villavicencio, G. Lopez, K.L. Strong, D. Prieto-Merino,
337 S. Cousens, R.E. Black, L. Liu, Global, regional, and national causes of under-5 mortality
338 in 2000–19: an updated systematic analysis with implications for the Sustainable
339 Development Goals, *Lancet Child Adolesc. Health.* 6 (2022) 106–115.
340 [https://doi.org/10.1016/S2352-4642\(21\)00311-4](https://doi.org/10.1016/S2352-4642(21)00311-4).
- 341 [3] A. Watson, T.M.A. Wilkinson, Respiratory viral infections in the elderly, *Ther. Adv.*
342 *Respir. Dis.* 15 (2021) 175346662199505. <https://doi.org/10.1177/1753466621995050>.
- 343 [4] A.R. Falsey, Y. Murata, E.E. Walsh, Impact of rapid diagnosis on management of adults
344 hospitalized with influenza, *Arch. Intern. Med.* 167 (2007) 354–360.
345 <https://doi.org/10.1001/archinte.167.4.ioi60207>.
- 346 [5] N. Zhang, L. Wang, X. Deng, R. Liang, M. Su, C. He, L. Hu, Y. Su, J. Ren, F. Yu, L. Du,
347 S. Jiang, Recent advances in the detection of respiratory virus infection in humans, *J. Med.*
348 *Virol.* 92 (2020) 408–417. <https://doi.org/10.1002/jmv.25674>.
- 349 [6] E.A. Karlsson, Review of global influenza circulation, late 2019 to 2020, and the impact of
350 the COVID-19 pandemic on influenza circulation, (2021).
351 <https://www.who.int/publications/i/item/who-wer-9625-241-264>.
- 352 [7] H. Sakamoto, M. Ishikane, P. Ueda, Seasonal Influenza Activity During the SARS-CoV-2
353 Outbreak in Japan, *JAMA.* 323 (2020) 1969. <https://doi.org/10.1001/jama.2020.6173>.
- 354 [8] D.A. Foley, D.K. Yeoh, C.A. Minney-Smith, A.C. Martin, A.O. Mace, C.T. Sikazwe, H.
355 Le, A. Levy, H.C. Moore, C.C. Blyth, The Interseasonal Resurgence of Respiratory

- 356 Syncytial Virus in Australian Children Following the Reduction of Coronavirus Disease
357 2019–Related Public Health Measures, *Clin. Infect. Dis.* 73 (2021) e2829–e2830.
358 <https://doi.org/10.1093/cid/ciaa1906>.
- 359 [9] D. Kim, J. Quinn, B. Pinsky, N.H. Shah, I. Brown, Rates of Co-infection Between SARS-
360 CoV-2 and Other Respiratory Pathogens, *JAMA.* 323 (2020) 2085.
361 <https://doi.org/10.1001/jama.2020.6266>.
- 362 [10] B. Alosaimi, A. Naeem, M.E. Hamed, H.S. Alkadi, T. Alanazi, S.S. Al Rehily, A.Z.
363 Almutairi, A. Zafar, Influenza co-infection associated with severity and mortality in
364 COVID-19 patients, *Viol. J.* 18 (2021) 127. <https://doi.org/10.1186/s12985-021-01594-0>.
- 365 [11] World Health Organization, WHO: Influenza at the human-animal interface, (2022).
366 [https://cdn.who.int/media/docs/default-source/influenza/human-animal-interface-risk-](https://cdn.who.int/media/docs/default-source/influenza/human-animal-interface-risk-assessments/influenza-at-the-human-animal-interface-summary-and-assessment--from-14-may-to-27-june-2022.pdf?sfvrsn=bdf329be_3&download=true)
367 [assessments/influenza-at-the-human-animal-interface-summary-and-assessment--from-14-](https://cdn.who.int/media/docs/default-source/influenza/human-animal-interface-risk-assessments/influenza-at-the-human-animal-interface-summary-and-assessment--from-14-may-to-27-june-2022.pdf?sfvrsn=bdf329be_3&download=true)
368 [may-to-27-june-2022.pdf?sfvrsn=bdf329be_3&download=true](https://cdn.who.int/media/docs/default-source/influenza/human-animal-interface-risk-assessments/influenza-at-the-human-animal-interface-summary-and-assessment--from-14-may-to-27-june-2022.pdf?sfvrsn=bdf329be_3&download=true).
- 369 [12] I. Mena, M.I. Nelson, F. Quezada-Monroy, J. Dutta, R. Cortes-Fernández, J.H. Lara-
370 Puente, F. Castro-Peralta, L.F. Cunha, N.S. Trovão, B. Lozano-Dubernard, A. Rambaut, H.
371 van Bakel, A. García-Sastre, Origins of the 2009 H1N1 influenza pandemic in swine in
372 Mexico, *ELife.* 5 (2016) e16777. <https://doi.org/10.7554/eLife.16777>.
- 373 [13] J.D. Diaz-Decaro, N.M. Green, H.A. Godwin, Critical evaluation of FDA-approved
374 respiratory multiplex assays for public health surveillance, *Expert Rev. Mol. Diagn.* 18
375 (2018) 631–643. <https://doi.org/10.1080/14737159.2018.1487294>.
- 376 [14] H.H. Mostafa, K.C. Carroll, R. Hicken, G.J. Berry, R. Manji, E. Smith, J.L. Rakeman, R.C.
377 Fowler, M. Leelawong, S.M. Butler-Wu, D. Quintero, M. Umali-Wilcox, R.W.
378 Kwiatkowski, D.H. Persing, F. Weir, M.J. Loeffelholz, Multicenter Evaluation of the

- 379 Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV Test, *J. Clin. Microbiol.* 59 (2021) e02955-
380 20. <https://doi.org/10.1128/JCM.02955-20>.
- 381 [15] US Center for Diseases control and Prevention, US Center for Diseases control and
382 Prevention Lab Alert: Changes_CDC_RT-PCR_SARS-CoV-2_Testing, (2021).
383 [https://www.cdc.gov/csels/dls/locs/2021/07-21-2021-lab-alert-Changes_CDC_RT-](https://www.cdc.gov/csels/dls/locs/2021/07-21-2021-lab-alert-Changes_CDC_RT-PCR_SARS-CoV-2_Testing_1.html)
384 [PCR_SARS-CoV-2_Testing_1.html](https://www.cdc.gov/csels/dls/locs/2021/07-21-2021-lab-alert-Changes_CDC_RT-PCR_SARS-CoV-2_Testing_1.html).
- 385 [16] Wales Government, Public health approach to respiratory viruses including COVID-19,
386 2022 to 2023, (2022). [https://gov.wales/public-health-approach-respiratory-viruses-](https://gov.wales/public-health-approach-respiratory-viruses-including-covid-19-2022-2023)
387 [including-covid-19-2022-2023](https://gov.wales/public-health-approach-respiratory-viruses-including-covid-19-2022-2023).
- 388 [17] A. Hammond, V. Cozza, S. Hirve, M.-J. Medina, D. Pereyaslov, W. Zhang, Global
389 Influenza Programme, World Health Organization, Geneva, Switzerland, Leveraging
390 Global Influenza Surveillance and Response System for the COVID-19 Pandemic Response
391 and Beyond, *China CDC Wkly.* 3 (2021) 937–940.
392 <https://doi.org/10.46234/ccdcw2021.226>.
- 393 [18] World Health Organization/Global Influenza Surveillance and Response System, WHO
394 End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance, (2022).
395 <https://apps.who.int/iris/handle/10665/351409>.
- 396 [19] K.A. Stellrecht, S.M. Nattanmai, J. Butt, V.P. Maceira, A.A. Espino, A.J. Castro, A.
397 Landes, N. Dresser, S.A. Butt, Effect of genomic drift of influenza PCR tests, *J. Clin. Virol.*
398 93 (2017) 25–29. <https://doi.org/10.1016/j.jcv.2017.05.016>.
- 399 [20] M. Kidd, A. Richter, A. Best, N. Cumley, J. Mirza, B. Percival, M. Mayhew, O. Megram,
400 F. Ashford, T. White, E. Moles-Garcia, L. Crawford, A. Bosworth, S.F. Atabani, T. Plant,
401 A. McNally, S-Variant SARS-CoV-2 Lineage B.1.1.7 Is Associated With Significantly

- 402 Higher Viral Load in Samples Tested by TaqPath Polymerase Chain Reaction, *J. Infect.*
403 *Dis.* 223 (2021) 1666–1670. <https://doi.org/10.1093/infdis/jiab082>.
- 404 [21] Cepheid, Xpert Xpress SARS-CoV-2/Flu/RSV Instructions for Use, (2021).
405 <https://www.fda.gov/media/142437/download>.
- 406 [22] ThermoFisher Scientific, TaqPath™ COVID-19, FluA, FluB Combo Kit
407 Instruction for use, (2022). <https://www.fda.gov/media/145931/download>.
- 408 [23] KogeneBiotech, PowerChekTMSARS-CoV-2, Influenza A&B, RSV Multiplex Real-time
409 PCR Kit II Instructions for use, (2021).
410 https://www.kogene.co.kr/eng/sub/product/covid-19/sars-cov-2_influenza_rsv.asp.
- 411 [24] V.M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.K. Chu, T. Bleicker, S.
412 Brünink, J. Schneider, M.L. Schmidt, D.G. Mulders, B.L. Haagmans, B. van der Veer, S.
413 van den Brink, L. Wijsman, G. Goderski, J.-L. Romette, J. Ellis, M. Zambon, M. Peiris, H.
414 Goossens, C. Reusken, M.P. Koopmans, C. Drosten, Detection of 2019 novel coronavirus
415 (2019-nCoV) by real-time RT-PCR, *Eurosurveillance.* 25 (2020).
416 <https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045>.
- 417 [25] H. Auerswald, S. Yann, S. Dul, S. In, P. Dussart, N.J. Martin, E.A. Karlsson, J.A. Garcia-
418 Rivera, Assessment of inactivation procedures for SARS-CoV-2, *J. Gen. Virol.* 102 (2021).
419 <https://doi.org/10.1099/jgv.0.001539>.
- 420 [26] World Health Organisation, WHO information for the molecular detection of influenza
421 viruses, (2021). [https://cdn.who.int/media/docs/default-source/influenza/molecular-
422 detention-of-influenza-
423 viruses/protocols_influenza_virus_detection_feb_2021.pdf?sfvrsn=df7d268a_5](https://cdn.who.int/media/docs/default-source/influenza/molecular-detection-of-influenza-viruses/protocols_influenza_virus_detection_feb_2021.pdf?sfvrsn=df7d268a_5).

- 424 [27] World Health Organisation, WHO strategy for global respiratory syncytial virus
425 surveillance project based on the influenza platform, (2019).
426 [https://www.who.int/publications/i/item/who-strategy-for-global-respiratory-syncytial-](https://www.who.int/publications/i/item/who-strategy-for-global-respiratory-syncytial-virus-surveillance-project-based-on-the-influenza-platform)
427 [virus-surveillance-project-based-on-the-influenza-platform](https://www.who.int/publications/i/item/who-strategy-for-global-respiratory-syncytial-virus-surveillance-project-based-on-the-influenza-platform).
- 428 [28] H.G. Heine, A.J. Foord, J. Wang, S. Valdeter, S. Walker, C. Morrissy, F.Y.K. Wong, B.
429 Meehan, Detection of highly pathogenic zoonotic influenza virus H5N6 by reverse-
430 transcriptase quantitative polymerase chain reaction, *Viol. J.* 12 (2015) 18.
431 <https://doi.org/10.1186/s12985-015-0250-3>.
- 432 [29] S. Um, J.Y. Siegers, B. Sar, S. Chin, S. Patel, S. Bunnary, M. Hak, S. Sor, O. Sokhen, S.
433 Heng, D. Chau, T. Sothyra, A. Khalakdina, J.A. Mott, S.J. Olsen, F. Claes, L. Sovann, E.A.
434 Karlsson, Human Infection with Avian Influenza A(H9N2) Virus, Cambodia, February
435 2021, *Emerg. Infect. Dis.* 27 (2021) 2742–2745. <https://doi.org/10.3201/eid2710.211039>.
- 436 [30] F. Wolters, M. Grünberg, M. Huber, H.H. Kessler, F. Prüller, L. Saleh, C. Fébreau, J.
437 Rahamat-Langendoen, V. Thibault, W.J.G. Melchers, European multicenter evaluation of
438 Xpert® Xpress SARS-CoV-2/Flu/RSV test, *J. Med. Virol.* 93 (2021) 5798–5804.
439 <https://doi.org/10.1002/jmv.27111>.
- 440 [31] E.C. Leung, V.C. Chow, M.K. Lee, K.P. Tang, D.K. Li, R.W. Lai, Evaluation of the Xpert
441 Xpress SARS-CoV-2/Flu/RSV Assay for Simultaneous Detection of SARS-CoV-2,
442 Influenza A and B Viruses, and Respiratory Syncytial Virus in Nasopharyngeal Specimens,
443 *J. Clin. Microbiol.* 59 (2021) e02965-20. <https://doi.org/10.1128/JCM.02965-20>.
- 444 [32] T.Y. Kim, J.-Y. Kim, H.J. Shim, S.A. Yun, J.-H. Jang, H.J. Huh, J.-W. Kim, N.Y. Lee,
445 Comparison of the PowerChek SARS-CoV-2, Influenza A&B, RSV Multiplex Real-time
446 PCR Kit and BioFire Respiratory Panel 2.1 for simultaneous detection of SARS-CoV-2,

447 influenza A and B, and respiratory syncytial virus, *J. Virol. Methods*. 298 (2021) 114304.

448 <https://doi.org/10.1016/j.jviromet.2021.114304>.

449 [33] T.M. Uyeki, H.H. Bernstein, J.S. Bradley, J.A. Englund, T.M. File, A.M. Fry, S.

450 Gravenstein, F.G. Hayden, S.A. Harper, J.M. Hirshon, M.G. Ison, B.L. Johnston, S.L.

451 Knight, A. McGeer, L.E. Riley, C.R. Wolfe, P.E. Alexander, A.T. Pavia, *Clinical Practice*

452 *Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis,*

453 *Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal*

454 *Influenzaa*, *Clin. Infect. Dis.* 68 (2019) e1–e47. <https://doi.org/10.1093/cid/ciy866>.

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474 **FIGURE LEGENDS**

475 **FIGURE 1:** Distribution of cycle threshold (Ct)-values (median; min-max) in clinical samples
476 according to each RT-PCR assay. Standards of Care (SoC) are displayed in dark orange,
477 Thermofisher TaqPathTM COVID-19, FluA/B, RSV Combo Kit (TP) in light blue, Kogene
478 PowerChekTM SARS-CoV-2, Influenza A&B, RSV Multiplex Real-time PCR Kit II (PC) in light
479 orange, Cephied Xpert® Xpress SARS-CoV-2, Flu, RSV Kit (GX) in grey. Ct values are
480 displayed for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respiratory

481

TABLE 1: Genes targeted for each virus and each assay

	SARS-CoV-2	Influenza A	Influenza B	RSV
SOC	E; RdRp*	M	M	M for RSV A/RSV B**
FAO	-	M	-	-
GX[†]	E; N2; RdRp	M; PA; PB2	M; NSP	N for RSV A/RSV B
TP[‡]	N; S	M	M	N for RSV A M for RSV B
PC[†]	RdRp	M	NP	N for RSV A/RSV B

Legend: SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; IAV: Influenza A virus ; IBV: Influenza B virus ; RSV A/B: respiratory syncytial virus A/B; SoC: standard of care; FAO: Food and Agriculture Organization of United Nations; GX: Xpert® Xpress SARS-CoV-2, Flu, RSV Kit; TP: TaqPath™ COVID-19, Flu A/B, RSV Combo Kit; PC: PowerChek™ SARS-CoV-2, Influenza A&B, RSV Multiplex Real-time PCR Kit II; E: Envelop; M: Matrix; N: nucleocapsid; NP: nucleoprotein; NSP: non-structural protein; PA: polymerase acidic protein; PB2: polymerase basic protein; RdRp: RNA-dependent RNA polymerase; S: spike.

MPAs target one, two or three genes for detection of each SARS-CoV-2, IAV, IBV and RSV.

* SoC use two sets of primers and probes performed in two separate wells/PCR runs for each sample for detection of SARS-CoV-2; ** SoC use different optical channels to detect the RSV targets and then provide separate results for RSV A and RSV B; [†] GX and PC use separate optical channels to detect SARS-CoV-2, IAV, IBV and RSV and provide results for each virus separately; [‡] TP uses one optical detection channel for the detection of IAV and IBV and provides a combined result for influenza A/B, and similarly one optical channel is used for detection of RSV A and RSV B providing a combined result for RSV.

TABLE 2: Comparison of limit of detection between evaluated and standard assays

Virus	Host	Subtype	Lineage	FAO	GX	TP	PC	
SARS-CoV-2	Human	Wuhan	Indian, B.6, 2000	Not done	0	0	0	
		Alpha	2021	Not done	-1	1	1	
		Omicron	BA.2, 2022	Not done	0	0	0	
Influenza	Human seasonal influenza	A/H1N1	pdm, 2019	-2	-1	1	1	
		A/H3N2	2019	1	0	0	1	
		A/H3N2	2022	0	-1	0	0	
		B/Vic	Victoria	Not done	1	0	1	
		B/Yam	Yamagata	Not done	1	2	1	
	Avian influenza in human cases	A/H5N1	2.3.2.1c 2014	0	2	1	1	
		A/H9N2	G9/BJ94 2021	1	0	1	2	
		Avian influenza in poultry samples	A/H5N1	2.3.2.1c 2021	0	0	0	1
			A/H5N8	2.3.4.4b 2022	0	0	0	0
			A/H7N4	Jiangsu 2018	0	-1	-1	0

Legend: FAO: Food and Agriculture Organization of United Nations recommended primers and probes developed by the Australian Center for Disease Prevention for the detection of M gene from avian influenza; GX: Xpert® Xpress SARS-CoV-2, Flu, RSV Kit; TP: TaqPath™ COVID-19, FluA/B, RSV Combo Kit; PC PowerChek™ SARS-CoV-2, Influenza A&B, RSV Multiplex Real-time PCR Kit II; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

The table presents the difference between SoC and evaluated assay in term of Log10 dilution. Delta LoD resulted in 0 if MPA and SoC had the same LoD (in light green), ≥ 1 if LoD of MPA was lower than SoC (in dark green) and <0 if LoD of MPA was higher than SoC (in red).

TABLE 3: Comparison of evaluated assay and standard WHO/GIRS assays currently used in the laboratory

		Sensitivity	Specificity	Positive predictive value	Negative predictive value	Overall percent agreement
SARS-CoV-2	GX	96.6 (88.3-99.6)	100.0 (93.7-100.0)	100.0 (97.8-100.0)	98.8 (95.7-99.9)	99.1 (97.0-99.9)
	TP	96.6 (88.3-99.6)	100.0 (98.0-100.0)	100.0 (93.7-100.0)	98.9 (96.0-99.9)	99.2 (97.0-99.9)
	PC	95.0 (85.9-98.9)	99.4 (96.9-100.0)	98.2 (90.6-100.0)	98.4 (95.3-99.7)	98.3 (95.8-99.5)
Influenza A virus	GX	100.0 (93.3-100.0)	100.0 (98.0-100.0)	100 (93.3-100.0)	100.0 (98.0-100.0)	100.0 (98.4-100.0)
	PC	100.0 (95.7-100.0)	99.4 (96.9-100.0)	98.8 (93.6-100.0)	100.0 (98.1-100.0)	99.6 (98.0-100.0)
Influenza B virus	GX	100.0 (47.8-100.0)	100 (98.2-100.0)	100.0 (47.8-100.0)	100.0 (98.2-100.0)	100.0 (98.2-100.0)
	PC	100.0 (47.8-100.0)	98.6 (96.1-99.7)	62.5 (24.5-91.5)	100.0 (98.3-100.0)	98.7 (96.2-99.7)
InfluenzaA/B	TP*	100.0 (96.0-100.0)	100.0 (98.0-100.0)	100.0 (97.9-100.0)	100.0 (97.9-100.0)	100.0 (98.6-100.0)
Respiratory syncytial virus	GX	87.5 (71.0-96.5)	100.0 (97.8-100.0)	100.0 (87.7-100.0)	97.6 (94.0-99.3)	97.9 (94.8-99.4)
	TP	96.9 (83.8-99.9)	100.0 (97.9-100.0)	100.0 (88.8-100.0)	99.4 (96.9-100.0)	99.5 (97.4-100.0)
	PC	100.0 (89.1-100.0)	99.4 (96.9-100.0)	97.0 (84.2-99.9)	100.0 (97.9-100.0)	99.5 (97.4-100.0)

Legend: SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; GX: Xpert® Xpress SARS-CoV-2, Flu, RSV Kit; TP: TaqPath™ COVID-19, FluA/B, RSV Combo Kit; PC: PowerChek™ SARS-CoV-2, Influenza A&B, RSV Multiplex Real-time PCR Kit II; FAO: Food and Agriculture Organization of United Nations recommended primers and probes developed by the Australian Center for Disease Prevention for the detection of M gene from avian influenza.

* TP provides a combine influenza result for IAV and IBV as targets are combined in the same optical detection channel. Therefore, IAV and IBV results were combined for statistical tests.

TABLE 4: Comparison of multiplex assays with regards to test specifications, costs and accomplishment

	Standard assay	TaqPath	Powerchek	Xpert Xpress
Manufacturer	-	Thermo Fisher Scientific	Kogene Biotech	Cepheid
Pathogen detection	SARS-CoV-2, IAV, IBV RSVA and RSVB	SARS-CoV-2, InfluenzaA/B, RSV	SARS-CoV-2, IAV, IBV RSV	SARS-CoV-2, IAV, IBV RSV
Number of PCR reactions	4	1	1	1
Sample volume	Not specified *	400 µl	Not specified *	300 µl
Elution volume	Not specified *	50 µl	Not specified*	<i>Not applicable</i>
RNA volume	25µl (5 µl/each [‡])	17.5 µl	5 µl	<i>Not applicable</i>
Internal control	Not provided	Provided	Provided	Provided in cartridge
Step to add IC	Extraction	Extraction	PCR mix	<i>Not applicable</i>
Number of samples tested on the same assay	93	94	94	1
Run on time	90 min	90 min	90 min	36 min
Time to result*	540 minutes**	145 min**	145 min**	40 min
Personnel training	Low	High	Low	Low
RT-PCR Instrument	Any with > 2 optical channels	Applied Biosystems™ 7500 Fast; QuantStudio™5; QuantStudio™ 7 Flex, 384-well block	Any with 4 optical channels	GenXpert Instrument
Interpretation of results with software	RT-PCR Instrument	Pathogen Interpretive	RT-PCR Instrument	GenXpert Instrument
Cost reagents per test (US\$)	20 ^{†‡}	25 ^{††}	13.6 ^{††}	31 [‡]

*Sample volume according to the extraction kit manufacturer manual for use; ** Extraction 35 min, PCR 90 min each, interpretation of results 10 min for SoC, 20 min for MP

Providing that we perform 5 RT-PCR assays (2 PCR for SARS-CoV-2 (E and RdRP genes); 1 for IAV; 1 for IBV; and 1 for RSV) for Standard of care with 5µl for each RT-PCR

† We calculated a cost of 4 \$ per test in Standard PCR assay. ††Shipment and controls in each PCR plate included. ‡ Shipment included

Prices provided by Singapore for TP, Korea for PC and France for GX.

